Expedited decision on Tysabri?
Executive Summary
FDA says it is trying to complete its review of Biogen Idec/Elan's Tysabri before the new June 28, 2006 review deadline. Natalizumab's user fee date is being extended 90 days to review changes to the drug's risk management plan. The Tysabri application is a "high priority" and FDA is "working intensively to complete review of this new information and will attempt to do so before the end of the 90-day extension period," the agency says. Re-launch of the multiple sclerosis drug is now slated for the third quarter...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.